Novartis reports positive multiple sclerosis results with its BTK inhibitor

Novartis announced that its BTK inhibitor has shown a positive outcome in a multiple sclerosis study, marking a notable advance for the company in this therapeutic area.

The result highlights the growing interest in Bruton’s tyrosine kinase inhibitors as a potential disease‑modifying approach for multiple sclerosis, a condition that still lacks fully effective treatments.

The brief also notes other biotech developments, including new drug‑pricing agreements announced by the Trump administration and GSK’s accelerated work on an mRNA flu vaccine, underscoring a busy week in the sector.